## Claims

- 1. \ Substantially purified form of the polypeptide that comprising the amino-acid sequence shown in SEQ ID NO.  $\frac{3,4,8}{1,4,6}$  or 9, homologue thereof, fragment thereof or homologue of the fragment.
- 2. A polypeptide according to claim 1 that consists (comprising) of 3,4,8 the amino-acid sequence shown in SEQ ID NO. 1,4,6 or 9.
  - 3. A cDNA encoding the polypeptide according to claim 1.
- 4. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO.  $\frac{1500}{27577}$  or 10 or a fragment cDNA selectively hybridized to the cDNA.
- 5. A cDNA according to claim 3 that comprising the nucleotide 2 7 sequence shown in SEQ ID NO. 3 or 8 or a fragment cDNA selectively hybridized to the cDNA.
- 6. A replication or expression vector carrying the cDNA according to claim 3 to 5.
- 7. A host cell transformed with the replication or expression vector according to claim 6.
- 2 which comprises culturing a host cell according to claim 1 or effective to express the polypeptide according to claim 1 or 2.
  - 9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.
- according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.
  - 11. A pharmaceutical composition for the treatment of abnormal growth of smooth muscle cell, containing a polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or

carrier.

- 12. A pharmaceutical composition for the treatment of arteriosclerosis, restenosis after PTCA or myosarcoma, containing the polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or carrier.
- 13. A screening method for an antagonist or agonist of the polypeptide according to claim 1 or 2 with using the said polypeptide.

idi pu